AARTIPHARM Share Price Performance
₹0
-946.90 (-100.00%)
Price ₹0
Fair Value₹740.00
Share Pricen/a
New Narrative • Jun 01
Aarti Pharmalabs Limited Stock Price
- 1 Narratives written by author
- 0 Comments on narratives written by author
- 7 Fair Values set on narratives written by author
AARTIPHARM Community Narratives
AN
Fair Value
·Fair Value ₹740 10.8% undervalued intrinsic discount
CDMO Expansion And Xanthine Capacity Will Support Long Term Earnings Resilience
0users have liked this narrative
0users have commented on this narrative
2users have followed this narrative
CDMO Expansion And Xanthine Capacity Will Support Long Term Earnings Resilience
Aarti Pharmalabs is building out its contract manufacturing and a key ingredient business, aiming to serve more global demand and win work closer to real product launches. The upside comes from fuller factories and stickier customer projects, but delays, cost overruns, and pricing pressure could hold back profits.Read more
AN
₹740
10.8% undervalued intrinsic discount
Fair Value
Revenue
13.79% p.a.
Profit Margin
8.99%
Future PE
39.67x
Price in 2029
₹1.05k
Trending Discussion
No trending discussion available.
Recently Updated Narratives
AN
CDMO Expansion And Xanthine Capacity Will Support Long Term Earnings Resilience
Fair Value: ₹740 10.8% undervalued intrinsic discount
2 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
Snowflake Analysis
Aarti Pharmalabs Limited Key Details
About AARTIPHARM
- Founded
- 2019
- Employees
- 2162
- CEO
- WebsiteView website
Aarti Pharmalabs Limited, together with its subsidiaries, manufactures and sells active pharmaceutical ingredients, pharmaceutical intermediates, and xanthine derivatives in India and internationally. The company offers active pharmaceutical ingredients for various therapeutic areas, such as cardiovascular, anti-asthmatic, anti-cancer, anti-coagulant, anti-diabetic, arthritis, central nervous system agent, skincare, overactive bladder, calcimimetic, decongestant, anti-thalassaemic, analgesic, and ophthalmologic medications. It also provides contract development and manufacturing services for drug substance projects. In addition, the company offers intermediates; xanthine derivatives, including caffeine, theophylline anhydrous, aminophylline, etophylline, and theophylline; and acid and allied products, including sulphuric acid, sulphur trioxide, oil, dimethyl sulphate, diethyl sulphate, and sodium vinyl sulfonate. The company was formerly known as Aarti Organics Limited. Aarti Pharmalabs Limited was incorporated in 2019 and is headquartered in Mumbai, India.
